{"id":457503,"date":"2020-08-03T00:00:00","date_gmt":"2020-08-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0027-2020-biopharma-colorectal-cancer-unmet-need-us-eu5-2020\/"},"modified":"2026-04-19T11:22:41","modified_gmt":"2026-04-19T11:22:41","slug":"unneon0027-2020-biopharma-colorectal-cancer-unmet-need-us-eu5-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0027-2020-biopharma-colorectal-cancer-unmet-need-us-eu5-2020\/","title":{"rendered":"Colorectal Cancer | Unmet Need | US\/EU5 | 2020"},"content":{"rendered":"<p>This Unmet Need report focuses on the treatment of previously treated <em>RAS<\/em> and <em>BRAF<\/em>\u00a0 mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatment practices for metastatic colorectal cancer include the determination of tumor gene status for <em>RAS<\/em> (<em>KRAS<\/em> \/ <em>NRAS<\/em>) and <em>BRAF\u00a0\u00a0<\/em>mutation-positive patients. In second- and later-line settings, <em>RAS <\/em>and <em>BRAF <\/em>mutation-positive patients are treated with anti-VEGF therapies, such as Avastin (Genentech\/Roche), Cyramza (Eli Lilly), Stivarga (Bayer), and Zaltrap (Sanofi \/ Regeneron), with or without chemotherapy. The novel treatment regimen, consisting of BRAF + MEK inhibitors, Braftovi + Mektovi (Pfizer \/ Array BioPharma), in combination with the anti-EGFR therapies Erbitux (Eli Lilly \/ Merck KGaA) or Vectibix (Amgen), is recommended for the subsequent treatment of <em>BRAF\u00a0\u00a0<\/em>mutation-positive patients. Nevertheless, less-toxic, more-efficacious therapies are needed for the subsequent treatment of these two colorectal cancer subpopulations.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for previously treated <em>RAS <\/em>\/ <em>BRAF\u00a0\u00a0<\/em>mutation-positive metastatic colorectal cancer?<\/li>\n<li>What drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for previously treated<em> RAS<\/em> \/\u00a0<em>BRAF\u00a0\u00a0<\/em>mutation-positive metastatic colorectal cancer?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in previously treated <em>RAS<\/em> \/ <em>BRAF\u00a0\u00a0<\/em>mutation-positive metastatic colorectal cancer?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new <em> RAS <\/em>\/ <em>BRAF\u00a0\u00a0<\/em>mutation-positive metastatic colorectal cancer drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 32 European medical oncologists fielded in April 2020<\/p>\n<p><strong>Key companies: <\/strong>Pfizer \/ Array BioPharma, Eli Lilly \/ Merck KGaA, Amgen, Roche \/ Genentech, Bayer, Taiho\u00a0 Pharmaceutical<\/p>\n<p><strong>Key drugs: <\/strong>Braftovi, Erbitux, Vectibix, Avastin, Cyramza, Stivarga, Lonsurf<\/p>\n","protected":false},"template":"","class_list":["post-457503","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457503\/revisions"}],"predecessor-version":[{"id":457860,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457503\/revisions\/457860"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=457503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}